China draft guidance clarifies multi-region clinical trials
This article was originally published in Scrip
Executive Summary
The China FDA has released for comment provisional draft guidance on the conduct of multi-regional clinical trials, amid growing industry concerns about additional administrative layers and further delays in new drug approvals.